Introduction
The insulin-like growth factor-1 receptor (IGF-1R) is a tetrameric transmembrane receptor tyrosine kinase that is widely expressed in normal human tissues and is upregulated in a number of human cancers including colorectal, non-small cell lung, ovarian and pediatric cancers. The receptor is composed of two and two subunits linked by disulfide bonds in which the extracellular subunit is responsible for ligand binding and the subunit consists of a transmembrane domain and a cytoplasmic tyrosine kinase domain. Ligand binding activates the tyrosine kinase activity of IGF-1R
and results in transsubunit autophosphorylation and stimulation of signaling cascades that include PI3K-mTOR and MAPK pathways. Activation of IGF-1R has been reported to stimulate proliferation, survival, transformation, metastasis and angiogenesis, whereas inhibition of IGF-1R has been shown to impede tumorigenesis in several human xenograft models (1) .
Increased expression of IGF-1R and its cognate ligands, IGF-I and IGF-II has
been demonstrated in a wide range of solid tumors and hematologic neoplasias relative to normal tissue levels. Epidemiologic studies have shown an increased risk for the development of colon, lung, breast and bladder cancers with increased circulating levels of IGF-I (2-5). Additionally, IGF-1R expression levels have been correlated to poor prognosis in renal cell carcinoma (6, 7) . IGF-1R signaling mechanism has also been linked to resistance to various anti-tumor therapies including epidermal growth factor receptor inhibitors (1, 6, 8, 9) .
Similarly, the insulin receptor (IR) is composed of a heterotetramer consisting of two extracellular -subunits and two transmembrane -subunits. Binding of insulin to the IR extracellular -subunit causes a conformational change bringing together the two -subunits. Activated IR tyrosine kinase phosphorylates several intracellular substrates including IRS-1-4, Shc, Gab1 and Cbl. These phosphorylated proteins provide a docking site for effector proteins containing Src homology 2 (SH2) domains further linking IR to PI3-kinase (PI3K) via the regulatory p85 subunit. Homology between IR and IGF-IR ranges from 45-65% in the ligand binding domains to 60-85% in tyrosine kinase domains. Expression of IR is highest in adipose tissue and to a lesser extent in liver, heart and muscle (10) . Overexpression of IR in breast, colon, lung, ovarian and thyroid cancers suggest a role of IR in tumor progression (10) . More recently we have shown that forced overexpression of IR is tumorigenic in mice (11) .
OSI-906 is a potent and highly selective tyrosine kinase inhibitor that exhibits similar biochemical potency against IGF-1R (8 nM) and IR (14 nM) and is greater than 4 orders of magnitude more selective for IGF-1R/IR compared to a wide number of other receptor and non-receptor kinases (12) . Within a panel of >180 kinases only IGF-1R and IR were inhibited by greater than 50% at 1.0 M OSI-906. Inhibition of cell proliferation and induction of apoptosis following exposure to OSI-906 appears to be directly linked to inhibition of AKT in colorectal, lung, and pancreatic cancer cell lines (1, 12 , and then randomized for treatment studies. Measurement of volume was performed using high resolution ultrasound imaging as described (14) . Mice were treated when the tumors reached ~200 mm xenografts compared to controls (Fig. 1A) , but no growth changes were observed in the non-responsive NCI-H441 xenografts (Fig. 1B) . We found that NCI-H292 tumors had considerably higher levels of pIGF-1R and pIR than NCI-H441 tumors (Fig. 1C) . 
treatment resulted in a rapid and dose dependent inhibition of uptake of the radiotracer in the NCI-H292 cell line (Fig. 2A) Figure   2D . We observed a significant decrease in phosphorylation of AKT and S6 suggesting a correlation between decreased glucose uptake and inhibition of targets downstream of IGF-1R and IR. NCI-H292 cells treated at lower concentrations (10 nm -5 μM) over 2, 12 and 24 hours, demonstrated target inhibition at all concentrations at 2 hours, and sustained inhibition of pIGF-1R at both 12 and 24 hours for all concentrations except 10 nM (Fig. 3) . 
Correlation with target pathway inhibition: Target inhibition of both pIGF-1R and pIR
by a single dose of OSI-906 at 60 mg/kg in vivo in NCI-H292 xenograft tumors is shown in Fig. 5A . The data show that at 2 and 4 hours post treatment target inhibition of pIGF-1R is > 80% with 30% inhibition observed at 24 hours (Fig. 5B) . The effect on pIR is equally pronounced, demonstrating significant target inhibition of this receptor. Target inhibition of pIR was > 80% at 4 hours post treatment with 40% inhibition observed at 24 hours. Inhibition of both target receptors correlated with decreased uptake of 18 FDG in the same tumor samples analyzed. Figure 5C shows the results of a Western blot from tumor lysates at selected time points from mice bearing the NCI-H292 xenografts that were treated with 60mg/kg OSI-906 (n = 4/group). We found reduced activation levels of untreated control lysates. Importantly, Western blot analysis of OSI-906 treated NCI-H441 tumor xenografts, which do express very low levels of the target receptor, showed no reduction in pAKT levels at any time point compared to control (Fig. S1) Pharmacokinetic Analysis: Table S1 shows the drug concentration in the plasma samples from the NCI-H292 xenografts remained at a constant concentration ~20 μM Therefore, activation of AKT is likely the most important signaling event in relation to cellular metabolism, because AKT is sufficient to drive glycolysis and lactate formation and suppress macromolecular degradation in cancer (23, 24) . It has been shown that various therapeutic agents that disrupt the PI3K/AKT pathway, either directly or upstream of PI3K/AKT lead to decreased glucose uptake in tumors as measured by 18 FDG-PET (25) . Furthermore, the ability to inhibit FDG uptake in tumors has been shown to correlate well with treatment response in a number of cancers. As a consequence, 18 FDG-PET has been used clinically in cancer patients to predict response to various therapies via the ability of agents to disrupt glucose metabolism and glucose uptake in tumors (22, (26) (27) (28) The primary purpose of these studies was to determine if 18 FDG-PET could be used as an early, non-invasive PD biomarker for the dual kinase inhibitor OSI-906. We first determined in vitro using the sensitive cell line, NCI-H292 that a rapid decrease in Western blot analysis and showed a significant reduction in pIGF-1R, pIR, pAKT, pS6, and pERK 1/2. Target inhibition of these markers strongly link IGF-1R and IR to the PI3 kinase and AKT pathways and resultant changes in metabolic activity of cultured cells when exposed to OSI-906.
In vivo, decreased uptake of however, the increased levels were not statistically significant (p>0.5). As expected, similarly evaluated vehicle treated mice did not exhibit elevated glucose levels when evaluated at 2 hrs and 4 hrs (Fig. S2A) . Importantly, 18 FDG uptake in NCI-H441 tumors, which are insensitive to OSI-906, was similar in both OSI-906-treated and vehicletreated tumors. The fact that post-treatment 18 FDG uptake in these mice was not decreased when compared to baseline imaging suggests that the somewhat elevated circulating glucose levels had no detectable impact on 18 FDG uptake in this study. As further evidence, no change in 18 FDG uptake was seen in skeletal muscle following OSI-906 (Fig. S2B) , and only a slight increase in liver 18 FDG uptake was seen at 2 and 4 hours before returning to baseline at 24 hours (Fig. S2C ). Nonetheless, it is possible that human trials incorporating 18 FDG PET as a biomarker of response to OSI-906 may benefit from measurement of blood glucose levels, as the effects on 18 FDG uptake in patient studies could be larger than we observed in mice. 
